AJTMH ASTMH MEMBERSHIP INFORMATION: astmh@astmh.org
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 53(5), 1995, pp. 522-525
Copyright © 1995 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Luxemburger, C.
Right arrow Articles by White, N. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Luxemburger, C.
Right arrow Articles by White, N. J.

Oral Artesunate in the Treatment of Uncomplicated Hyperparasitemic Falciparum Malaria

C. Luxemburger, F. Nosten, Shotar, D. Raimond, T. Chongsuphajaisiddhi AND N. J. White
Shoklo Malaria Research Unit, Mae Sod, Thailand; Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand; Medecins Sans Frontieres, Paris, France; Center for Tropical Medicine, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom

Patients with uncomplicated hyperparasitemic falciparum malaria are usually given parenteral antimalarial treatment to prevent a progression to vital organ dysfunction and death. Since the oral artemisinin derivatives are more rapidly effective than other antimalarial drugs, we compared oral artesunate (4 mg/kg/day for three days with mefloquine 25 mg/kg on the second day) with an intravenous quinine loading dose (20 mg of salt/kg initially then 10 mg/kg every 8 hr, followed by mefloquine 25 mg/kg) in an open paired randomized trial in 60 patients with acute falciparum malaria and greater than 4% parasitemia, but no evidence of vital organ dysfunction. There were no deaths and none of the patients progressed to develop severe malaria. Oral artesunate treatment resulted in shorter median [range] times to fever clearance (19 hr [4–45] versus 47 hr [4–107]) (P < 0.0001), parasite clearance (36 hr [18–61] versus 82 hr [36–140]) (P < 0.0001), and discharge from the hospital (25 hr [12–44] versus 58 hr [24–115]) (P < 0.0001). There was no toxicity attributable to artesunate. The cure rates by day 28 were 70% (19 of 27) and 39% (11 of 27) in the artesunate and quinine groups, respectively (relative risk = 1.7; 95% confidence interval = 1.0–3.0). Oral artesunate was simpler, cheaper, safer, and more effective than intravenous quinine for the treatment of uncomplicated hyperparasitemia.




This article has been cited by other articles:


Home page
 BMJHome page
F. Nosten, E. Ashley, R. McGready, and R. Price
We still need artesunate monotherapy.
BMJ, July 1, 2006; 333(7557): 45 - 45.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the American Society of Tropical Medicine and Hygiene.